A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

Lingfang Xia, Qi Zhou, Yunong Gao, Wenjing Hu, Ge Lou, Hong Sun, Jianqing Zhu, Jin Shu, Xianfeng Zhou, Rong Sun and Xiaohua Wu ()
Additional contact information
Lingfang Xia: Fudan University Shanghai Cancer Center
Qi Zhou: Affiliated Tumor Hospital of Chongqing University
Yunong Gao: Beijing Cancer Hospital
Wenjing Hu: Nanjing Drum Tower Hospital
Ge Lou: Affiliated Tumor Hospital of Harbin Medical University
Hong Sun: Obstetrics & Gynecology Hospital of Fudan University
Jianqing Zhu: Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Jin Shu: Affiliated Tumor Hospital of Chongqing University
Xianfeng Zhou: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Rong Sun: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Xiaohua Wu: Fudan University Shanghai Cancer Center

Nature Communications, 2022, vol. 13, issue 1, 1-9

Abstract: Abstract This phase 2 study assesses the efficacy and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (anti-angiogenic agent) in women with pretreated recurrent or metastatic cervical cancer (ClinicalTrials.gov NCT03827837). Patients with histologically or cytologically confirmed cervical squamous cell carcinoma experiencing relapse or progression during or after 1–2 lines of systemic therapy for recurrent or metastatic disease are enrolled. Eligible patients receive camrelizumab 200 mg intravenously on day 1 of each 3-week cycle plus famitinib 20 mg orally once daily. The primary endpoint is the objective response rate. Secondary endpoints are duration of response, disease control rate, time to response, progression-free survival, overall survival, and safety. The trial has met pre-specified endpoint. Thirty-three patients are enrolled; median follow-up lasts for 13.6 months (interquartile range: 10.0–23.6). Objective responses are observed in 13 (39.4%, 95% confidence interval [CI]: 22.9–57.9) patients; the 12-month duration of response rate is 74.1% (95% CI: 39.1–90.9). Median progression-free survival is 10.3 months (95% CI: 3.5–not reached) and the 12-month overall survival rate is 77.7% (95% CI: 58.9–88.7). All patients experience treatment-related adverse events; grade ≥3 events occur in 26 (78.8%) patients. Treatment-related serious adverse events and deaths are observed in 9 (27.3%) and 2 (6.1%) patients, respectively. Camrelizumab plus famitinib shows promising antitumor activity with a manageable and tolerable safety profile in patients with pretreated recurrent or metastatic cervical squamous cell carcinoma. This combination may represent a treatment option for this population.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-35133-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-35133-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-35133-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().